
1653

| IPF 101 | | | | | | | | | | | | |
|--|---|------------------------|--|--------------|----------------|------------------|--|--|--|--|--|--|
| TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT Ocket No. RLL-124CIPUS | | | | | | | | | | | | |
| In Application of: RAMPAL et al. | | | | | | | | | | | | |
| Application No. | | Filing Date | Examiner | Customer No. | Group Art Unit | Confirmation No. | | | | | | |
| 09/973,265 | | 10/9/2001 | LUKTON, David | 26815 | 1653 | | | | | | | |
| Title: | A STABLE | ORAL PHARMACE | UTICAL COMPOSITION CON | TAINING OM | EPRAZOLE | | | | | | | |
| | | | Address to: | | | | | | | | | |
| | | | Commissioner for Paten P.O. Box 1450 Alexandria, VA 22313-14 | | | | | | | | | |
| | | | 37 CFR 1.97(b) | | | | | | | | | |
| I. ☑ . | 1. The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114. | | | | | | | | | | | |
| | | | 37 CFR 1.97(c) | | | · | | | | | | |
| 2. | The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of: | | | | | | | | | | | |
| | ☐ the | statement specified i | n 37 CFR 1.97(e); | | | | | | | | | |
| | | | OR | | | | | | | | | |
| | ☐ the f | fee set forth in 37 CF | R 1.17(p). | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |

TRANSMITTÁL OF INFORMATION DISCLOSURE STATEMENT Docket No. (Under 37 CFR 1.97(b) or 1.97(c)) **RLL-124CIPUS** RAMPAL et al. Group Art Unit Confirmation No. Filing Date Examiner Customer No. Application No. 1653 10/9/2001 LUKTON, David 26815 09/973,265 Title: A STABLE ORAL PHARMACEUTICAL COMPOSITION CONTAINING OMEPRAZOLE Payment of Fee (Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p)) A check in the amount of is attached. ★ The Director is hereby authorized to charge and credit Deposit Account No. 50-0912 as described below. Charge the amount of Credit any overpayment. \boxtimes Charge any additional fee required. X☐ Payment by credit card. Form PTO-2038 is attached. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. Certificate of Mailing by First Class Mail Certificate of Transmission by Facsimile* I hereby certify that this correspondence is being deposited I certify that this document and authorization to charge deposit with the United States Postal Service with sufficient postage account is being facsimile transmitted to the United States as first class mail in an envelope addressed to Patent and Trademark Office (Fax. No. "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-14! August 23, 2004 (Date) Signature of Person Mailing Correspondence Signature Christine Kenedy Typed or Printed Name of Person Mailing Certificate Typed or Printed Name of Person Signing Certificate *This certificate may only be used if paying by deposit account. Dated: August 23, 2004 William D. Hare, Esq. Reg. No. 44,739 Ranbaxy Inc. 600 College Road East, Suite 2100 Princeton, New Jersey 08540 Telephone: (609) 720-5378 Facsimile: (609) 514-9779 CC:



Docket No.: RLL-124CIPUS

Serial No.: 09/973,265

Applicants: Rampal et al.

Filed: 10/9/2001

Group: 1653

| | | | U.S. P | ATENT DOCUMENTS | | | |
|---------------------|----------|-----------------|-------------|---------------------------|---------------|-------------|----------------------------|
| EXAMINER INITIAL | • | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
| | SA1 | 6,605,303 | 8/12/2003 | Karehill et al. | 424 | 484 | |
| ·-· | - | | | | | | |
| · | <u> </u> | | | | | | * |
| | | - | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | l | <u> </u> | FOREIGN | PATENT DOCUMEN | TS | | |
| | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION YES NO |
| | | | | | | | |
| | | | | | | | |
| | | | | | _ | | · |
| | | | | | | | |
| | | OTHER DOCUME | NTS (Includ | ding Author, Title, Date, | , Pertinent P | ages, Etc.) | |
| | | | | | | | • |
| | | | | | | | |
| · . | - | | | | | | |
| | | | | | | | |
| | | · | | | | | |

| EXAMINER | DATE CONSIDERED |
|----------|-----------------|
|----------|-----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.